Clinical Trials · NCT01269047
Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Albert Einstein College of Medicine
- Enrollment
- 37
- Start date
- Aug 2009
- Locations
- 1 site, United States
- Primary endpoint
- Post-prandial Blood Glucose Concentration in Both Pramlintide and Exenatide Treated Groups in Acute and Chronic Setting, Compared to Insulin Monotherapy in Type 1 Diabetes Mellitus.